Cargando…
Return on Investment of the COVID-19 Vaccination Campaign in New York City
IMPORTANCE: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 out...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679875/ https://www.ncbi.nlm.nih.gov/pubmed/36409495 http://dx.doi.org/10.1001/jamanetworkopen.2022.43127 |
_version_ | 1784834299967569920 |
---|---|
author | Sah, Pratha Vilches, Thomas N. Moghadas, Seyed M. Pandey, Abhishek Gondi, Suhas Schneider, Eric C. Singer, Jesse Chokshi, Dave A. Galvani, Alison P. |
author_facet | Sah, Pratha Vilches, Thomas N. Moghadas, Seyed M. Pandey, Abhishek Gondi, Suhas Schneider, Eric C. Singer, Jesse Chokshi, Dave A. Galvani, Alison P. |
author_sort | Sah, Pratha |
collection | PubMed |
description | IMPORTANCE: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks. OBJECTIVE: To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. EXPOSURES: An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. MAIN OUTCOMES AND MEASURES: Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI. RESULTS: During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. CONCLUSIONS AND RELEVANCE: Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic. |
format | Online Article Text |
id | pubmed-9679875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-96798752022-12-05 Return on Investment of the COVID-19 Vaccination Campaign in New York City Sah, Pratha Vilches, Thomas N. Moghadas, Seyed M. Pandey, Abhishek Gondi, Suhas Schneider, Eric C. Singer, Jesse Chokshi, Dave A. Galvani, Alison P. JAMA Netw Open Original Investigation IMPORTANCE: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks. OBJECTIVE: To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. EXPOSURES: An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. MAIN OUTCOMES AND MEASURES: Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI. RESULTS: During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. CONCLUSIONS AND RELEVANCE: Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic. American Medical Association 2022-11-21 /pmc/articles/PMC9679875/ /pubmed/36409495 http://dx.doi.org/10.1001/jamanetworkopen.2022.43127 Text en Copyright 2022 Sah P et al. JAMA Network Open. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License. |
spellingShingle | Original Investigation Sah, Pratha Vilches, Thomas N. Moghadas, Seyed M. Pandey, Abhishek Gondi, Suhas Schneider, Eric C. Singer, Jesse Chokshi, Dave A. Galvani, Alison P. Return on Investment of the COVID-19 Vaccination Campaign in New York City |
title | Return on Investment of the COVID-19 Vaccination Campaign in New York City |
title_full | Return on Investment of the COVID-19 Vaccination Campaign in New York City |
title_fullStr | Return on Investment of the COVID-19 Vaccination Campaign in New York City |
title_full_unstemmed | Return on Investment of the COVID-19 Vaccination Campaign in New York City |
title_short | Return on Investment of the COVID-19 Vaccination Campaign in New York City |
title_sort | return on investment of the covid-19 vaccination campaign in new york city |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679875/ https://www.ncbi.nlm.nih.gov/pubmed/36409495 http://dx.doi.org/10.1001/jamanetworkopen.2022.43127 |
work_keys_str_mv | AT sahpratha returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT vilchesthomasn returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT moghadasseyedm returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT pandeyabhishek returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT gondisuhas returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT schneiderericc returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT singerjesse returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT chokshidavea returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity AT galvanialisonp returnoninvestmentofthecovid19vaccinationcampaigninnewyorkcity |